Litigation Details for CELGENE CORPORATION v. MYLAN PHARMACEUTICALS INC. (D.N.J. 2019)
✉ Email this page to a colleague
CELGENE CORPORATION v. MYLAN PHARMACEUTICALS INC. (D.N.J. 2019)
Docket | ⤷ Try a Trial | Date Filed | 2019-12-30 |
Court | District Court, D. New Jersey | Date Terminated | 2021-07-22 |
Cause | 15:1126 Patent Infringement | Assigned To | Susan Davis Wigenton |
Jury Demand | None | Referred To | Leda Dunn Wettre |
Patents | 7,189,740; 7,465,800; 7,855,217; 7,968,569; 8,404,717; 8,530,498; 8,648,095; 9,056,120; 9,101,621; 9,101,622 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in CELGENE CORPORATION v. MYLAN PHARMACEUTICALS INC.
Biologic Drugs cited in CELGENE CORPORATION v. MYLAN PHARMACEUTICALS INC.
Details for CELGENE CORPORATION v. MYLAN PHARMACEUTICALS INC. (D.N.J. 2019)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2019-12-30 | 1 | Complaint | United States Patent Nos. 7,189,740 (“the ’740 patent”), 7,465,800 (“the ’800 patent”), 7,855,217 (“…’740 patent, the ’800 patent, the ’217 patent, the ’569 patent, the ’717 patent, the ’498 patent, the …740 patent, the ’800 patent, the ’217 patent, the ’569 patent, the ’717 patent, the ’498 patent, the…403 PageID: 2 patent”), 8,404,717 (“the ’717 patent”), 8,530,498 (“the ’498 patent”), 8,648,095 (“the…“the ’095 patent”), 9,056,120 (“the ’120 patent”), 9,101,621 (“the ’621 patent”), and 9,101,622 (“the | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |